

**Supplemental Table 1: Gleason Grade Group Characteristics**

Gleason Grade Groups (Prostatectomy Specimen)	All Patients		RP		PORT			
	N	%	N	%	N	%		
1	84	5.3	57	3.6	27	1.7		
2	423	26.7	275	17.3	148	9.3		
3	425	26.8	245	15.4	180	11.3		
4	212	13.4	140	8.8	72	4.5		
5	442	27.9	282	17.8	160	10.1		
Total	1586	100	999	63.0	587	37.0		
Gleason Grade Groups (Initial Prostate Biopsy)	All Patients		RP		PORT		RT	
	N	%	N	%	N	%	N	%
1	124	13.0	31	3.0	20	2.3	73	7.7
2	234	27.0	69	6.9	55	7.4	110	12.6
3	185	20.8	73	7.4	41	5.2	71	8.2
4	161	19.0	67	6.9	41	5.7	53	6.3
5	166	20.3	51	5.8	33	4.5	82	10.0
Total	870	100	291	30.1	190	25.2	389	44.8

**Supplemental Table 2:** <sup>68</sup>Ga-PSMA-11 Detection Rate in Prostate or Prostate Bed Stratified by PSA Level and Prior Therapy.

PSA range		Total			RP			PORT			RT		
		Negative	Positive	Total	Negative	Positive	Total	Negative	Positive	Total	Negative	Positive	Total
< 0.25 ng/mL	N	98	18	116	89	16	105	9	2	11			
% of total N		4.89	0.9	5.79	8.74	1.57	10.31	1.52	0.34	1.85			
% per column		6.69	3.33		11.01	7.62		1.75	2.53				
% per row		84.48	15.52		84.76	15.24		81.82	18.18				
0.25 - < 0.5 ng/mL	N	287	36	323	229	29	258	58	7	65			
% of total N		14.31	1.8	16.11	22.5	2.85	25.34	9.78	1.18	10.96			
% per column		19.6	6.65		28.34	13.81		11.28	8.86				
% per row		88.85	11.15		88.76	11.24		89.23	10.77				
0.5 - < 1.0 ng/mL	N	289	49	338	166	40	206	123	9	132			
% of total N		14.41	2.44	16.86	16.31	3.93	20.24	20.74	1.52	22.26			
% per column		19.74	9.06		20.54	19.05		23.93	11.39				
% per row		85.5	14.5		80.58	19.42		93.18	6.82				
1.0 - < 2.0 ng/mL	N	240	61	301	127	41	168	113	20	133			
% of total N		11.97	3.04	15.01	12.48	4.03	16.5	19.06	3.37	22.43			
% per column		16.39	11.28		15.72	19.52		21.98	25.32				
% per row		79.73	20.27		75.6	24.4		84.96	15.04				
2.0 - < 5.0 ng/mL	N	291	169	460	97	41	138	134	16	150	60	112	172
% of total N		14.51	8.43	22.94	9.53	4.03	13.56	22.6	2.7	25.3	15.23	28.43	43.65
% per column		19.88	31.24		12	19.52		26.07	20.25		42.25	44.44	
% per row		63.26	36.74		70.29	29.71		89.33	10.67		34.88	65.12	
5.0 - < 10.0 ng/mL	N	138	118	256	57	27	84	44	14	58	37	77	114
% of total N		6.88	5.89	12.77	5.6	2.65	8.25	7.42	2.36	9.78	9.39	19.54	28.93
% per column		9.43	21.81		7.05	12.86		8.56	17.72		26.06	30.56	
% per row		53.91	46.09		67.86	32.14		75.86	24.14		32.46	67.54	
≥10 ng/mL	N	121	90	211	43	16	59	33	11	44	45	63	108
% of total N		6.03	4.49	10.52	4.22	1.57	5.8	5.56	1.85	7.42	11.42	15.99	27.41
% per column		8.27	16.64		5.32	7.62		6.42	13.92		31.69	25	
% per row		57.35	42.65		72.88	27.12		75	25		41.67	58.33	
Total	N	1464	541	2005	808	210	1018	514	79	593	142	252	394
% of total N		73.02	26.98		79.37	20.63		86.68	13.32		36.04	63.96	

**Supplemental Table 3:** <sup>68</sup>Ga-PSMA-11 Detection Rate in Pelvic Lymph Nodes Stratified by PSA Level and Prior Therapy.

PSA range		Total			RP			PORT			RT		
		Negative	Positive	Total	Negative	Positive	Total	Negative	Positive	Total	Negative	Positive	Total
< 0.25 ng/mL	N	86	30	116	78	27	105	8	3	11			
% of total N		4.29	1.5	5.79	7.66	2.65	10.31	1.35	0.51	1.85			
% per column		7.71	3.37		13.38	6.21		2.74	1				
% per row		74.14	25.86		74.29	25.71		72.73	27.27				
0.25 - < 0.5 ng/mL	N	219	104	323	180	78	258	39	26	65			
% of total N		10.92	5.19	16.11	17.68	7.66	25.34	6.58	4.38	10.96			
% per column		19.62	11.7		30.87	17.93		13.36	8.64				
% per row		67.8	32.2		69.77	30.23		60	40				
0.5 - < 1.0 ng/mL	N	198	140	338	123	83	206	75	57	132			
% of total N		9.88	6.98	16.86	12.08	8.15	20.24	12.65	9.61	22.26			
% per column		17.74	15.75		21.1	19.08		25.68	18.94				
% per row		58.58	41.42		59.71	40.29		56.82	43.18				
1.0 - < 2.0 ng/mL	N	149	152	301	82	86	168	67	66	133			
% of total N		7.43	7.58	15.01	8.06	8.45	16.5	11.3	11.13	22.43			
% per column		13.35	17.1		14.07	19.77		22.95	21.93				
% per row		49.5	50.5		48.81	51.19		50.38	49.62				
2.0 - < 5.0 ng/mL	N	246	214	460	66	72	138	65	85	150	115	57	172
% of total N		12.27	10.67	22.94	6.48	7.07	13.56	10.96	14.33	25.3	29.19	14.47	43.65
% per column		22.04	24.07		11.32	16.55		22.26	28.24		47.72	37.25	
% per row		53.48	46.52		47.83	52.17		43.33	56.67		66.86	33.14	
5.0 - < 10.0 ng/mL	N	140	116	256	42	42	84	23	35	58	75	39	114
% of total N		6.98	5.79	12.77	4.13	4.13	8.25	3.88	5.9	9.78	19.04	9.9	28.93
% per column		12.54	13.05		7.2	9.66		7.88	11.63		31.12	25.49	
% per row		54.69	45.31		50	50		39.66	60.34		65.79	34.21	
≥10 ng/mL	N	78	133	211	12	47	59	15	29	44	51	57	108
% of total N		3.89	6.63	10.52	1.18	4.62	5.8	2.53	4.89	7.42	12.94	14.47	27.41
% per column		6.99	14.96		2.06	10.8		5.14	9.63		21.16	37.25	
% per row		36.97	63.03		20.34	79.66		34.09	65.91		47.22	52.78	
Total	N	1116	889	2005	583	435	1018	292	301	593	241	153	394
% of total N		55.66	44.34		57.27	42.73		49.24	50.76		61.17	38.83	

**Supplemental Table 4:** <sup>68</sup>Ga-PSMA-11 Detection Rate in Soft Tissue Metastases Stratified by PSA Level and Prior Therapy.

PSA range		Total			RP			PORT			RT		
		Negative	Positive	Total	Negative	Positive	Total	Negative	Positive	Total	Negative	Positive	Total
< 0.25 ng/mL	N	107	9	116	98	7	105	9	2	11			
% of total N		5.34	0.45	5.79	9.63	0.69	10.31	1.52	0.34	1.85			
% per column		6.93	1.95		11.34	4.55		2.22	1.06				
% per row		92.24	7.76		93.33	6.67		81.82	18.18				
0.25 - < 0.5 ng/mL	N	289	34	323	239	19	258	50	15	65			
% of total N		14.41	1.7	16.11	23.48	1.87	25.34	8.43	2.53	10.96			
% per column		18.72	7.38		27.66	12.34		12.35	7.98				
% per row		89.47	10.53		92.64	7.36		76.92	23.08				
0.5 - < 1.0 ng/mL	N	297	41	338	191	15	206	106	26	132			
% of total N		14.81	2.04	16.86	18.76	1.47	20.24	17.88	4.38	22.26			
% per column		19.24	8.89		22.11	9.74		26.17	13.83				
% per row		87.87	12.13		92.72	7.28		80.3	19.7				
1.0 - < 2.0 ng/mL	N	243	58	301	143	25	168	100	33	133			
% of total N		12.12	2.89	15.01	14.05	2.46	16.5	16.86	5.56	22.43			
% per column		15.74	12.58		16.55	16.23		24.69	17.55				
% per row		80.73	19.27		85.12	14.88		75.19	24.81				
2.0 - < 5.0 ng/mL	N	340	120	460	110	28	138	96	54	150	134	38	172
% of total N		16.96	5.99	22.94	10.81	2.75	13.56	16.19	9.11	25.3	34.01	9.64	43.65
% per column		22.02	26.03		12.73	18.18		23.7	28.72		48.73	31.93	
% per row		73.91	26.09		79.71	20.29		64	36		77.91	22.09	
5.0 - < 10.0 ng/mL	N	168	88	256	58	26	84	28	30	58	82	32	114
% of total N		8.38	4.39	12.77	5.7	2.55	8.25	4.72	5.06	9.78	20.81	8.12	28.93
% per column		10.88	19.09		6.71	16.88		6.91	15.96		29.82	26.89	
% per row		65.63	34.38		69.05	30.95		48.28	51.72		71.93	28.07	
≥10 ng/mL	N	100	111	211	25	34	59	16	28	44	59	49	108
% of total N		4.99	5.54	10.52	2.46	3.34	5.8	2.7	4.72	7.42	14.97	12.44	27.41
% per column		6.48	24.08		2.89	22.08		3.95	14.89		21.45	41.18	
% per row		47.39	52.61		42.37	57.63		36.36	63.64		54.63	45.37	
Total	N	1544	461	2005	864	154	1018	405	188	593	275	119	394
% of total N		77.01	22.99		84.87	15.13		68.3	31.7		69.8	30.2	

**Supplemental Table 5:** <sup>68</sup>Ga-PSMA-11 Detection Rate in Bone Metastases Stratified by PSA Level and Prior Therapy.

PSA range		Total			RP			PORT			RT		
		Negative	Positive	Total	Negative	Positive	Total	Negative	Positive	Total	Negative	Positive	Total
< 0.25 ng/mL	N	104	12	116	96	9	105	8	3	11			
% of total N		5.19	0.6	5.79	9.43	0.88	10.31	1.35	0.51	1.85			
% per column		6.59	2.8		11.21	5.56		1.86	1.85				
% per row		89.66	10.34		91.43	8.57		72.73	27.27				
0.25 - < 0.5 ng/mL	N	284	39	323	230	28	258	54	11	65			
% of total N		14.16	1.95	16.11	22.59	2.75	25.34	9.11	1.85	10.96			
% per column		18.01	9.11		26.87	17.28		12.53	6.79				
% per row		87.93	12.07		89.15	10.85		83.08	16.92				
0.5 - < 1.0 ng/mL	N	289	49	338	184	22	206	105	27	132			
% of total N		14.41	2.44	16.86	18.07	2.16	20.24	17.71	4.55	22.26			
% per column		18.33	11.45		21.5	13.58		24.36	16.67				
% per row		85.5	14.5		89.32	10.68		79.55	20.45				
1.0 - < 2.0 ng/mL	N	244	57	301	147	21	168	97	36	133			
% of total N		12.17	2.84	15.01	14.44	2.06	16.5	16.36	6.07	22.43			
% per column		15.47	13.32		17.17	12.96		22.51	22.22				
% per row		81.06	18.94		87.5	12.5		72.93	27.07				
2.0 - < 5.0 ng/mL	N	339	121	460	102	36	138	103	47	150	134	38	172
% of total N		16.91	6.03	22.94	10.02	3.54	13.56	17.37	7.93	25.3	34.01	9.64	43.65
% per column		21.5	28.27		11.92	22.22		23.9	29.01		46.21	36.54	
% per row		73.7	26.3		73.91	26.09		68.67	31.33		77.91	22.09	
5.0 - < 10.0 ng/mL	N	179	77	256	60	24	84	39	19	58	80	34	114
% of total N		8.93	3.84	12.77	5.89	2.36	8.25	6.58	3.2	9.78	20.3	8.63	28.93
% per column		11.35	17.99		7.01	14.81		9.05	11.73		27.59	32.69	
% per row		69.92	30.08		71.43	28.57		67.24	32.76		70.18	29.82	
≥10 ng/mL	N	138	73	211	37	22	59	25	19	44	76	32	108
% of total N		6.88	3.64	10.52	3.63	2.16	5.8	4.22	3.2	7.42	19.29	8.12	27.41
% per column		8.75	17.06		4.32	13.58		5.8	11.73		26.21	30.77	
% per row		65.4	34.6		62.71	37.29		56.82	43.18		70.37	29.63	
Total	N	1577	428	2005	856	162	1018	431	162	593	290	104	394
% of total N		78.65	21.35		84.09	15.91		72.68	27.32		73.6	26.4	

**Supplemental Table 6** Patient Characteristics of PSMA-positive Scans With or Without Histopathological Evaluation

	No Histology (PSMA-positive Scan)		Histology (PSMA-positive Scan)	
	N (%)	Median (IQR)	N	Median (IQR)
Prostatectomy (RP)	634 (46.7%)		44 (24.6%)	
PORT	429 (31.5%)		56 (31.3%)	
Radiation therapy (RT)	297 (21.8%)		79 (44.1%)	
Total	1360 (88.4%)		179 (11.6%)	
Age (years)	1360	70 (IQR 65 - 74)	179	70 (IQR 65 - 74)
PSA (ng/mL)	1360	2.2 (0.79 - 5.4)	179	3.11 (IQR 1.3 - 6.2)
PSA nadir (ng/mL)	889	0.08 (IQR < 0.1 - 0.4)	141	0.09 (IQR < 0.1 - 0.4)
T-stage (prostatectomy)	1343	7 (IQR 5 - 10)	157	6 (IQR 4 - 8)
Clinical T-stage	479	3 (IQR 3 - 5)	99	3 (IQR 3 - 4)
Gleason grade group (prostatectomy)	1043	3 (IQR 2 - 5)	99	3 (IQR 2 - 5)
Gleason grade group (biopsy)	757	3 (IQR 2 - 4)	113	2 (IQR 2 - 4)
PSMA inj. Dose (mCi)	1826	5.5 (IQR 5 - 6.2)	179	5.6 (IQR 5.1 - 6.3)
Locoregional disease present	1104 (81.2%)		151 (84.4%)	
Distant disease present	688 (50.6%)		70 (39.1%)	

T-stage nomenclature: T1 = 1, T1a = 2, T1b = 3, T1c = 4, T2 = 5, T2a = 6, T2b = 7, T2c = 8, T3 = 9, T3a = 10, T3b = 11, T4 = 12

**Supplemental Table 7** Characteristics of Histologically False Positive Lesions.

Number	Group	Region	Sampling method	Histology
1	RPT	Prostate region	Biopsy	Urethral anastomosis, negative for malignancy
2	RT	Prostate region	Biopsy	Prostate needle biopsy, negative for malignancy with radiation effect
3	RPT	Soft tissue	Surgery	Right perineal tissue, negative for malignancy
4	RT	Prostate region	Biopsy	Prostate needle biopsy, negative for malignancy
5	PORT	Pelvic nodes	Surgery	Salvage pelvic lymph node dissection, negative for malignancy
6	RPT	Prostate region	Biopsy	Prostate needle biopsy, negative for malignancy
7	RT	Prostate region	Biopsy	Prostate needle biopsy, negative for malignancy
8	RPT	Prostate region	Surgery	Benign tissue
9	RPT	Pelvic nodes	Surgery	Presacral lymph node, negative for malignancy
10	RPT	Soft tissue	Biopsy	Benign inguinal lymph nodes
11	PORT	Prostate region	Biopsy	Periprostatic mass, negative for malignancy
12	RPT	Pelvic nodes	Surgery	External iliac lymph nodes, negative for malignancy
13	RPT	Pelvic nodes	Surgery	Salvage pelvic lymph node dissection, negative for malignancy
14	RT	Prostate region	Biopsy	Prostate needle biopsy, negative for malignancy
15	RPT	Pelvic nodes	Surgery	Presacral lymph node, negative for malignancy
16	RT	Prostate region	Biopsy	Prostate needle biopsy, negative for malignancy
17	RT	Soft tissue	Biopsy	Retroperitoneal nodes, negative for malignancy
18	RT	Pelvic nodes	Surgery	Pelvic mass, negative for malignancy
19	PORT	Soft tissue	Biopsy	Mediastinal lymph nodes, negative for malignancy
20	RT	Soft tissue	Biopsy	Mediastinal benign granulosa cell tumor

21	RPT	Soft tissue	Biopsy	Benign inguinal lymph nodes
22	RT	Prostate region	Biopsy	Prostate needle biopsy, negative for malignancy
23	RPT	Soft tissue	Biopsy	Benign inguinal lymph nodes
24	PORT	Soft tissue	Biopsy	Benign inguinal lymph nodes
25	RPT	Pelvic nodes	Surgery	Salvage pelvic lymph node dissection, negative for malignancy
26	RPT	Pelvic nodes	Surgery	Salvage pelvic lymph node dissection, negative for malignancy
27	RT	Prostate region	Biopsy	Prostate needle biopsy, negative for malignancy
28	PORT	Pelvic nodes	Surgery	Salvage pelvic lymph node dissection, negative for malignancy
29	RT	Prostate region	Biopsy	Prostate needle biopsy, negative for malignancy
30	RT	Prostate region	Biopsy	Prostate needle biopsy, negative for malignancy with radiation effect
31	RT	Prostate region	Biopsy	Targeted seminal vesicle biopsy, negative for malignancy
32	RT	Prostate region	Biopsy	Prostate needle biopsy, negative for malignancy
33	PORT	Bone	Biopsy	Sacrum negative for malignancy



**Supplemental Table 8** Overall Disease Burden Listed as Number of Involved Regions by PSA.

PSA Range	N	Total					RP					PORT					RT								
		Negative	One Region	Two Regions	Three Regions	Four Regions	Total	Negative	One Region	Two Regions	Three Regions	Four Regions	Total	Negative	One Region	Two Regions	Three Regions	Four Regions	Total	Negative	One Region	Two Regions	Three Regions	Four Regions	Total
< 0.25 ng/mL	N	64	37	13	2	0	116	61	31	11	2	0	105	3	6	2	0	0	11						
	% of total N	3.2	1.9	0.7	0.1		5.8	6.0	3.1	1.1	0.2		10.3	0.5	1.0	0.3			1.9						
	% neg./pos.	13.6	4.0	2.9	1.5			18.0	6.8	6.2	6.1			2.7	2.1	1.3									
	% in PSA range	55.2	31.9	11.2	1.7			58.1	29.5	10.5	1.9			27.3	54.6	18.2									
0.25 - < 0.5 ng/mL	N	159	122	36	5	1	323	137	93	24	3	1	258	22	29	12	2	0	65						
	% of total N	7.9	6.1	1.8	0.3	0.1	16.1	13.5	9.1	2.4	0.3	0.1	25.3	3.7	4.9	2.0	0.3		11.0						
	% neg./pos.	33.8	13.1	8.1	3.8	4.0		40.4	20.4	13.6	9.1	7.7		20.0	10.1	8.1	4.4								
	% in PSA range	49.2	37.8	11.2	1.6	0.3		53.1	36.1	9.3	1.2	0.4		33.9	44.6	18.5	3.1								
0.5 - < 1.0 ng/mL	N	104	192	40	1	1	338	70	114	21	0	1	206	34	78	19	1	0	132						
	% of total N	5.2	9.6	2.0	0.1	0.1	16.9	6.9	11.2	2.1		0.1	20.2	5.7	13.2	3.2	0.2		22.3						
	% neg./pos.	22.1	20.6	9.0	0.8	4.0		20.7	25.0	11.9		7.7		30.9	27.3	12.8	2.2								
	% in PSA range	30.8	56.8	11.8	0.3	0.3		34.0	55.3	10.2		0.5		25.8	59.1	14.4	0.8								
1.0 - < 2.0 ng/mL	N	66	160	60	12	3	301	40	92	29	5	2	168	26	68	31	7	1	133						
	% of total N	3.3	8.0	3.0	0.6	0.2	15.0	3.9	9.0	2.9	0.5	0.2	16.5	4.4	11.5	5.2	1.2	0.2	22.4						
	% neg./pos.	14.0	17.2	13.5	9.1	12.0		11.8	20.2	16.4	15.2	15.4		23.6	23.8	20.8	15.2	50.0							
	% in PSA range	21.9	53.2	19.9	4.0	1.0		23.8	54.8	17.3	3.0	1.2		19.6	51.1	23.3	5.3	0.8							
2.0 - < 5.0 ng/mL	N	49	244	125	38	4	460	19	75	32	10	2	138	19	76	40	14	1	150	11	93	53	14	1	172
	% of total N	2.4	12.2	6.2	1.9	0.2	22.9	1.9	7.4	3.1	1.0	0.2	13.6	3.2	12.8	6.8	2.4	0.2	25.3	2.8	23.6	13.5	3.6	0.3	43.7
	% neg./pos.	10.4	26.2	28.0	28.8	16.0		5.6	16.5	18.1	30.3	15.4		17.3	26.6	26.9	30.4	50.0		50.0	49.2	44.2	26.4	10.0	
	% in PSA range	10.7	53.0	27.2	8.3	0.9		13.8	54.4	23.2	7.3	1.5		12.7	50.7	26.7	9.3	0.7		6.4	54.1	30.8	8.1	0.6	
5.0 - < 10.0 ng/mL	N	20	114	87	29	6	256	10	37	31	4	2	84	5	17	27	9	0	58	5	60	29	16	4	114
	% of total N	1.0	5.7	4.3	1.5	0.3	12.8	1.0	3.6	3.1	0.4	0.2	8.3	0.8	2.9	4.6	1.5		9.8	1.3	15.2	7.4	4.1	1.0	28.9
	% neg./pos.	4.3	12.2	19.5	22.0	24.0		3.0	8.1	17.5	12.1	15.4		4.6	5.9	18.1	19.6			22.7	31.8	24.2	30.2	40.0	
	% in PSA range	7.8	44.5	34.0	11.3	2.3		11.9	44.1	36.9	4.8	2.4		8.6	29.3	46.6	15.5			4.4	52.6	25.4	14.0	3.5	
≥10 ng/mL	N	9	62	85	45	10	211	2	14	29	9	5	59	1	12	18	13	0	44	6	36	38	23	5	108
	% of total N	0.5	3.1	4.2	2.2	0.5	10.5	0.2	1.4	2.9	0.9	0.5	5.8	0.2	2.0	3.0	2.2		7.4	1.5	9.1	9.6	5.8	1.3	27.4
	% neg./pos.	1.9	6.7	19.1	34.1	40.0		0.6	3.1	16.4	27.3	38.5		0.9	4.2	12.1	28.3			27.3	19.1	31.7	43.4	50.0	
	% in PSA range	4.3	29.4	40.3	21.3	4.7		3.4	23.7	49.2	15.3	8.5		2.3	27.3	40.9	29.6			5.6	33.3	35.2	21.3	4.6	
Total	N	471	931	446	132	25	2005	339	456	177	33	13	1018	110	286	149	46	2	593	22	189	120	53	10	394
	% of total N	23.5	46.4	22.2	6.6	1.3		33.3	44.8	17.4	3.2	1.3		18.6	48.2	25.1	7.8	0.3		5.6	48.0	30.5	13.5	2.5	

Regions may represent either prostate/bed, pelvic lymph nodes, soft tissue metastases and/or bone metastases.

**Supplemental Table 9** Locoregional Disease Burden (Prostate/Prostate Bed and/or Pelvic Lymph Nodes) by PSA.

PSA range	Total			RP			PORT			RT			
	Negative	Positive	Total	Negative	Positive	Total	Negative	Positive	Total	Negative	Positive	Total	
< 0.25 ng/mL	N	73	43	116	67	38	105	6	5	11			
% of total N		3.6	2.1	5.8	6.6	3.7	10.3	1.0	0.8	1.9			
% per column		9.8	3.4		15.5	6.5		2.5	1.4				
% per row		62.9	37.1		63.8	36.2		54.6	45.5				
0.25 - < 0.5 ng/mL	N	191	132	323	158	100	258	33	32	65			
% of total N		9.5	6.6	16.1	15.5	9.8	25.3	5.6	5.4	11.0			
% per column		25.6	10.5		36.6	17.1		13.8	9.1				
% per row		59.1	40.9		61.2	38.8		50.8	49.2				
0.5 - < 1.0 ng/mL	N	154	184	338	87	119	206	67	65	132			
% of total N		7.7	9.2	16.9	8.6	11.7	20.2	11.3	11.0	22.3			
% per column		20.6	14.6		20.1	20.3		27.9	18.4				
% per row		45.6	54.4		42.2	57.8		50.8	49.2				
1.0 - < 2.0 ng/mL	N	107	194	301	52	116	168	55	78	133			
% of total N		5.3	9.7	15.0	5.1	11.4	16.5	9.3	13.2	22.4			
% per column		14.3	15.4		12.0	19.8		22.9	22.1				
% per row		35.6	64.5		31.0	69.1		41.4	58.7				
2.0 - < 5.0 ng/mL	N	127	333	460	38	100	138	52	98	150	37	135	172
% of total N		6.3	16.6	22.9	3.7	9.8	13.6	8.8	16.5	25.3	9.4	34.3	43.7
% per column		17.0	26.5		8.8	17.1		21.7	27.8		50.0	42.2	
% per row		27.6	72.4		27.5	72.5		34.7	65.3		21.5	78.5	
5.0 - < 10.0 ng/mL	N	59	197	256	23	61	84	15	43	58	21	93	114
% of total N		2.9	9.8	12.8	2.3	6.0	8.3	2.5	7.3	9.8	5.3	23.6	28.9
% per column		7.9	15.7		5.3	10.4		6.3	12.2		28.4	29.1	
% per row		23.1	77.0		27.4	72.6		25.9	74.1		18.4	81.6	
≥10 ng/mL	N	35	176	211	7	52	59	12	32	44	16	92	108
% of total N		1.8	8.8	10.5	0.7	5.1	5.8	2.0	5.4	7.4	4.1	23.4	27.4
% per column		4.7	14.0		1.6	8.9		5.0	9.1		21.6	28.8	
% per row		16.6	83.4		11.9	88.1		27.3	72.7		14.8	85.2	
Total	N	746	1259	2005	432	586	1018	240	353	593	74	320	394
% of total N		37.2	62.8		42.4	57.6		40.5	59.5		18.8	81.2	

**Supplemental Table 10** Distant Disease Burden (Soft Tissue and/or Bone Metastases) by PSA.

PSA range		Total			RP			PORT			RT		
		Negative	Positive	Total	Negative	Positive	Total	Negative	Positive	Total	Negative	Positive	Total
< 0.25 ng/mL	N	100	16	116	93	12	105	7	4	11			
% of total N		5.0	0.8	5.8	9.1	1.2	10.3	1.2	0.7	1.9			
% per column		8.0	2.1		12.5	4.4		2.3	1.4				
% per row		86.2	13.8		88.6	11.4		63.6	36.4				
0.25 - < 0.5 ng/mL	N	256	67	323	214	44	258	42	23	65			
% of total N		12.8	3.3	16.1	21.0	4.3	25.3	7.1	3.9	11.0			
% per column		20.6	8.8		28.8	16.0		14.1	7.8				
% per row		79.3	20.7		83.0	17.1		64.6	35.4				
0.5 - < 1.0 ng/mL	N	252	86	338	170	36	206	82	50	132			
% of total N		12.6	4.3	16.9	16.7	3.5	20.2	13.8	8.4	22.3			
% per column		20.2	11.3		22.9	13.1		27.4	17.0				
% per row		74.6	25.4		82.5	17.5		62.1	37.9				
1.0 - < 2.0 ng/mL	N	201	100	301	127	41	168	74	59	133			
% of total N		10.0	5.0	15.0	12.5	4.0	16.5	12.5	10.0	22.4			
% per column		16.1	13.2		17.1	14.9		24.8	20.1				
% per row		66.8	33.2		75.6	24.4		55.6	44.4				
2.0 - < 5.0 ng/mL	N	255	205	460	82	56	138	68	82	150	105	67	172
% of total N		12.7	10.2	22.9	8.1	5.5	13.6	11.5	13.8	25.3	26.7	17.0	43.7
% per column		20.5	27.0		11.0	20.4		22.7	27.9		51.5	35.3	
% per row		55.4	44.6		59.4	40.6		45.3	54.7		61.1	39.0	
5.0 - < 10.0 ng/mL	N	118	138	256	43	41	84	18	40	58	57	57	114
% of total N		5.9	6.9	12.8	4.2	4.0	8.3	3.0	6.8	9.8	14.5	14.5	28.9
% per column		9.5	18.2		5.8	14.9		6.0	13.6		27.9	30.0	
% per row		46.1	53.9		51.2	48.8		31.0	69.0		50.0	50.0	
≥10 ng/mL	N	64	147	211	14	45	59	8	36	44	42	66	108
% of total N		3.2	7.3	10.5	1.4	4.4	5.8	1.4	6.1	7.4	10.7	16.8	27.4
% per column		5.1	19.4		1.9	16.4		2.7	12.2		20.6	34.7	
% per row		30.3	69.7		23.7	76.3		18.2	81.8		38.9	61.1	
Total	N	1246	759	2005	743	275	1018	299	294	593	204	190	394
% of total N		62.1	37.9		73.0	27.0		50.4	49.6		51.8	48.2	